BridgeMD
A Phase 1/2 Study of Pumitamig alone or in Combination with Ipilimumab in First-Line HCC
EU CTIS ID: 2025-523602-33-00
What this study is testing
The main goal of phase 1 is to see if it is safe for people with liver cancer to take pumitamig with ipilimumab, and to find the best dose to use, while the main goal of phase 2 is to see which treatment works better at shrinking liver cancer: pumitamig with ipilimumab, pumitamig alone, or atezolizumab with bevacizumab.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age of Participant must be ≥ 18 years of age, or legal adult age according to the local regulation inclusive, at the time of signing the ICF.
- People with a certain kind of advanced liver cancer (HCC) that can't be removed by surgery.
- People who can still do most everyday things on their own.
- People whose liver is working well.
- People who haven't had certain treatments for their liver cancer before.
- People who have at least one tumor that shows up on a scan.
You likely can't join if
- People with rare types of liver cancer.
- People who have serious bleeding problems or are likely to bleed easily.
- People who have had an organ transplant or have immune system diseases.
- People with high blood pressure that can’t be controlled, even with medicine.
- People whose urine has too much protein (sign of kidney problems).
- People taking strong blood-thinning medicines.
The study team makes the final eligibility decision.
Where it's taking place
- China
- United Kingdom
- Taiwan
- Singapore
- Korea, Democratic People's Republic of
- United States
- Australia
- Chile
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include China; United Kingdom; Taiwan; Singapore; Korea, Democratic People's Republic of; United States and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.